THERAPEUTIC EFFECT OF 5A-REDUCTASE INHIBITOR COMBINED WITH DOCETAXEL IN THE TREATMENT OF PROSTATE CANCER

Objective: This study investigated the efficacy of 5 alpha-reductase inhibitors combined with docetaxel in the treatment of prostate cancer, providing a new solution for clinical drug use. Methods: In total, 76 patients with prostate cancer were treated with endocrine and chemotherapy after surgical castration. According to the different drugs used after castration, patients were divided into the observation group and control group. The observation group was treated with a 5 alpha-reductase inhibitor (finasteride) in combination with docetaxel, and the control group was treated with bicalutamide in combination with docetaxel. Results: Compared with the control group, the total effective rate was significantly increased in the treatment group (P<0.05). PSA was in the normal range, and the symptoms of urinary obstruction and bone pain were significantly relieved (P<0.05). KPS scores increased significantly at each time point (P<0.05), and the progression-free survival time and median survival time were also significantly increased (P<0 .05 ), and the differences were significant. Conclusion: We demonstrate that a 5 alpha-reductase inhibitor combined with docetaxel was effective in the treatment of prostate cancer and is worthy of clinical promotion.